New Trial – Allogeneic Bone Marrow Mesenchymal Stem Cell Injection for Sarcopenia
The phase 1/2 trial plans to enroll 30 participants to assess CG-BM1’s safety and tolerability, with two doses administered one month apart.
Trial at a glance
- Sponsor: GuangZhou Cellgenes Biotechnology Co., Ltd.
- Phase/Status: Phase 1/2; Recruiting.
- Indication: Sarcopenia; planned enrollment of 30 participants.
- Arms/Dosing: Two experimental CG-BM1 allogeneic human bone marrow mesenchymal stem cell injection arms: 5.0 × 10^7 cells/participant once a month for a total of 2 administrations; and 1.0 × 10^8 cells/participant once a month for a total of 2 administrations.
- Control: None.
- Endpoints: Primary: incidence of study-related adverse events and serious adverse events from the first administration of CG-BM1 through 30 days after the last administration.
- Timing: Actual start: April 30, 2026; estimated primary completion: June 30, 2029; estimated study completion: October 31, 2029.
Trial Summary
ClinicalTrials.gov lists the following summary for the linked study.
Stay updated on Orthobiologics news
Thanks! Your signup has been saved.
1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Sarcopenia. 2. To observe the preliminary effectiveness of CG-BM1 in treating Sarcopenia patients.
- Contact: Zeng Liping, Senior Medical Director; Ip.zeng@cellgenes.com; +86 20 82514048.
- Contact: Xue Yumei, Chief Physician; xymgdci@163.com; +86 13570082363.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
New Trial – Phase II Umbilical-Cord Stem Cells for Amyotrophic Lateral Sclerosis
New Trial – Intranasal Stem Cells for Perinatal Brain Injury and Cerebral Palsy
Made Scientific Acquires Resilience’s 85K-Square-Foot Cell Therapy Facility
Trial – MesenCell Bone Marrow Stem Cells Evaluated in Chronic Graft-Versus-Host DiseaseEditor’s Picks
Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND Soon
Inside Cellular Intelligence: The Zuck-Backed AI Company That Acquired Novo’s Parkinson’s Cell Therapy
Webinar: Scaling iPSC Therapies Without Scaling VariabilityOn-Demand
Aspen Neuroscience Publishes Preclinical Data on Parkinson’s iPSC-Derived Cell Therapy
